1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Bladder Cancer 2017

Bladder Cancer 2017

  • August 2017
  • ID: 5175286
  • Format: PDF
  • Firstword Pharma

Summary

Table of Contents

How will immune checkpoint inhibitors transform the treatment of Bladder Cancer?

Significant progress has been made over the past decade in bladder cancer as a host of new targeted therapies have emerged from the development pipeline. Five PD-1/PD-L1 immune checkpoint inhibitors have been approved but how are they set to impact treatment pathways? Which checkpoint inhibitor do the key opinion leaders (KOLs) think will dominate the market and how can each one successfully differentiate itself in a fast evolving landscape? Targeted agents such as Eli Lilly’s Cyramza are also in the pipeline but what are the most important factors to ensure utilisation of these novel agents?

Learn how KOLs see the market evolving, and how they expect developers to differentiate their marketed and pipeline therapies in KOL Insight: Bladder Cancer. Twelve US and European KOLs provide their candid insights on eight marketed products and four Phase III pipeline programmes


Take a tour of the report now:

Methodology >
Research Objectives >
Questions Asked >
See the RCC therapies covered >
Find out who the 6 US and 6 European KOLs are >
Sample Pages >

Top Takeaways

What unmet needs exist in non-muscle invasive bladder cancer (NMIBC) and is the BCG vaccine addressing these needs? Will the conventional Bacillus Calmette–Guérin (BCG) vaccine retain its hold as standard of care in the high-risk NMIBC setting?
Which novel intravesical therapies are likely to treat NMIBC in the future and will they be embraced? Instiladrin (FKD Therapies/Merck & Co.), Vicinium (Eleven Biotherapeutics) and ALT-803 (Altor BioScience) are all in the Phase III pipeline but how are they perceived by KOLs?
Five PD-1/PD-L1 checkpoint inhibitors have been approved for advanced bladder cancer but which ones are KOLs most enthusiastic about? Find out how the immune checkpoint inhibitors are expected to impact bladder cancer and how these agents are perceived by regulatory authorities?
How do KOLs believe the immune checkpoint inhibitors can successfully differentiate themselves? How are KOLs weighing up each checkpoint inhibitor in terms of efficacy, safety, administration and access? Find out which checkpoint inhibitor has the most opportunity in the adjuvant setting or as a maintenance approach.
Can targeted agents such as Eli Lilly’s Cyramza forge a niche in the treatment algorithm? Based on results of the RANGE study, how do KOLs view Cyramza (ramucirumab) as a potential treatment for bladder cancer? What will be critical for commercial success in this indication?
Which innovative mechanisms of action are KOLs most excited about? Angiogenesis inhibitors and fibroblast growth factor (FGF) receptor inhibitors are all in the early-stage pipeline but are there any novel mechanisms that stand out to KOLs?
How will future treatment pathways evolve for the treatment of bladder cancer? Find out if immune checkpoint inhibitors or combination therapies are expected to play an important role.


Quotes

“A lot of patients will have a PD-1 inhibitor upfront. There may be a small group of patients with metastatic and more aggressive disease, who will be having [upfront] combinations of PD-1 and CTLA-4 inhibitors, or possibly IDO inhibitors.” EU Key Opinion Leader

“It has been a hugely exciting time in the last two years. Suddenly, in bladder cancer, things are taking off. It’s really quite exciting.” US Key Opinion Leader


Marketed Therapies

Valstar (valrubicin; Endo Pharmaceuticals)
TheraCys/Immucyst (BCG vaccine; Sanofi Pasteur/Merck & Co.)
Javlor (vinflunine ditartrate; Pierre Fabre)
Tecentriq (atezolizumab; Roche)
Keytruda (pembrolizumab; Merck & Co.)
Opdivo (nivolumab; BMS)
Imfinzi (durvalumab; AstraZeneca)
Bavencio (avelumab; Merck KGaA/Pfizer)
Pipeline Therapies
Cyramza (ramucirumab; Eli Lilly)
Instiladrin (SCH 721015; FKD Therapies/Merck & Co.)
Vicinium (VB4-845; Eleven Biotherapeutics)
ALT-803 (Altor BioScience)
KOLs Interviewed
KOLs from North America
Dr. Robert Dreicer, MD; Deputy Director of University of Virginia (UVA) Cancer Center, Director of Solid Tumor Oncology within the division of Hematology/Oncology and Professor of Medicine and Urology, at the University of Virginia School of Medicine, Virginia
Dr. Donald Lamm, MD, FACP; Clinical Professor at the University of Arizona and Director of the BCG Oncology practice in Phoenix, Arizona
Dr. Arlene O Siefker-Radtke, MD; Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, Houston, Texas
Dr. Daniel Petrylak, MD; Professor of Medicine (Medical Oncology) and of Urology at Yale Cancer Center and Co-Director of the Signal Transduction Research Program, Yale University, New Haven, Connecticut
Dr. David I. Quinn MBBS, PhD, FRACP FACP; Medical Director of the Norris Cancer Hospital and Clinics, Head of the Section of Genitourinary Medical Oncology and Associate Professor of Medicine in the Division of Cancer Medicine and Blood Diseases at the Keck School of Medicine of the University of Southern California (USC), California
Anonymous, US KOL; Professor of Medicine at a leading Oncology Institute

KOLs from Europe

Professor Robert Huddart MA (Oxon), MBBS, MRCP, FRCR, PhD; Leader of the Clinical Academic Radiotherapy team at the Institute of Cancer Research (ICR) in London, UK
Professor Dr. Theo M de Reijke, MD, PhD, FEBU; Professor of Urology at the Academic Medical Center (AMC), Amsterdam, Netherlands
Professor Robert Jones, MBChB, PhD; Professor of Clinical Cancer Research (Clinical Trials Research) and Consultant in Medical Oncology at the University of Glasgow, UK
Professor Morgan Roupret, MD, PhD; Academic Professor of Urology, Hopital Pitié-Salpétrière at the University of Paris, France
Professor Dr. Shahrokh F. Shariat, MD; Professor and Chairman of the Department of Urology at the Medical University of Vienna, Austria
Anonymous, German KOL; Professor of Urology at a leading German Institute

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage. 
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update. 
Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report’s publication date. 
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date. 

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Nonmuscle invasive bladder cancer - Pipeline Insight, 2021

  • $ 2000
  • July 2021
  • 80 pages

“Nonmuscle invasive bladder cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Nonmuscle invasive bladder cancer pipeline landscape. ...

  • World
  • Bladder Cancer
  • Industry analysis

ref:plp2017

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on